You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
While the news of the BARDA contract drove a surge in T2's stock price, it was last month's NTAP decision that has company officials and analysts encouraged.
New resistance tests for Mycoplasma genitalium and gonorrhea could help stave off superbugs, but guidelines and economic factors may hinder adoption.
The new test uses the number of sequencing reads at specific early and late HPV transcripts as a biomarker for high-grade cytology.
The clearance of the Binx io CT/NG test marks a milestone for the Johns Hopkins University group that funds early-stage development of rapid STI testing.
The company provided updates on its newborn screening testing presence.
The firm provided updates on its bacterial pathogen detection and antimicrobial resistance testing for bacterial isolates and a direct-from-urine test.
The company said it is pushing to begin simultaneous clinical trials for multiple small panel-based tests for its sample-to-answer Savanna platform.
The system has been evaluated by researchers studying cervical cancer prevention as well as other HPV-related cancers, with positive feedback so far.
In an earnings call, the firm said it sees growth continuing for the BD Max, BD Cor, and Phoenix systems, and in China in general.
At the Henry Ford Health System in Southeast Michigan, bringing on the Roche Cobas Liat for flu testing led to a season of headaches before it started paying off.
Researchers in India plan to sequence SARS-CoV-2 isolates from around the country, according to LiveMint.
Mauro Ferrari has resigned as president of the European Research Council over its response to the COVID-19 pandemic, the Financial Times reports.
Stat News reports some health tech startups are laying off or furloughing workers.
In Genome Research this week: indels affecting microsatellites in cancer, analytical approach to find key regulatory elements, and more.